BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Carfilzomib: Phase III amended

Onyx amended the ongoing, open-label, European Phase III FOCUS trial to change the primary endpoint to OS from PFS and increase patient enrollment to 300 from 84. Onyx said it hopes to demonstrate a potential mortality benefit for carfilzomib. The trial is...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >